| n=31 |
---|---|
Age on enrolment (years) | |
 Minimum–maximum | 36–66 |
Sex | |
 Female | 28 (90%) |
 Male | 3 (10%) |
Ethnicity | |
 Black | 31 (100%) |
Diabetes status | |
 Pre-diabetic, unaware | 13 (42%) |
 Pre-diabetic, aware | 7 (23%) |
 Type 2 diabetic, unaware | 3 (10%) |
 Type 2 diabetic, aware | 8 (26%) |
Medication for diabetes (n=8) | |
 Metformin only | 2 |
 Metformin + sulphonylurea | 3 |
 Metformin + DPP-4* inhibitor | 2 |
 Sodium-glucose cotransporter-2 inhibitor | 1 |
Medication for pre-diabetes (n=7) | |
 Metformin only | 2 |
 Metformin + DPP-4* inhibitor | 1 |
 None | 4 |
Hypertension | 11 (35%) |
Medication for Hypertension (n = 11) | 11 |
Hypercholesterolaemia | 9 (29%) |
Medication for Hypercholesterolaemia (n=9) | |
 HMG-CoA reductase inhibitors | 4 |
 None | 5 |
*DPP-4-dipeptidyl peptidase-4 | Â |